Search - tctmd.com

Displaying 1 - 20 of 33

Sort: Relevancy | Date

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2024

Shelley Wood

July 31, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2023

Shelley Wood

May 31, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

Shelley Wood

October 03, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

Shelley Wood

January 31, 2022

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Caitlin E. Cox

October 11, 2021

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

Shelley Wood

June 22, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2021

Shelley Wood

May 31, 2021

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

Advertisement

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

TCTMD’s Top 10 Most Popular Stories for July 2024

TCTMD’s Top 10 Most Popular Stories for November 2023

What’s Going to Be Hot at AHA 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

TCTMD’s Top 10 Most Popular Stories for May 2023

What’s Going to Be Hot at ACC/WCC 2023?

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

TCTMD’s Top 10 Most Popular Stories for September 2022

What’s Going to Be Hot at ESC 2022?

TCTMD’s Top 10 Most Popular Stories for January 2022

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

TCTMD’s Top 10 Most Popular Stories for May 2021

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content